Schroder Investment Management Group
EGRX

Schroder Investment Management Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Schroder Investment Management Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,719
Closed -$370K – 1401
2020
Q2 		$370K Sell
7,719
-237,778
-97% -$11.9M ﹤0.01% 1033
2020
Q1 		$11.6M Buy
245,497
+197,592
+412% +$9.92M 0.02% 510
2019
Q4 		$2.88M Buy
+47,905
New +$2.86M ﹤0.01% 825
2017
Q4 		– Sell
-3,728
Closed -$219K – 1393
2017
Q3 		$219K Buy
+3,728
New +$226K ﹤0.01% 1182

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schroder Investment Management Group's EGRX Position: Q3 2020 in Review

Schroder Investment Management Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2020, closing a stake of 7,719 shares — an estimated $370K sold.

Schroder Investment Management Group first reported a position in EGRX in Q3 2017 and held it in 4 quarters. The position peaked at $11.6M in Q1 2020. 171 funds tracked by Wall St. Rank hold EGRX as of Q3 2020.

  • Schroder Investment Management Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Schroder Investment Management Group sold 7,719 Eagle Pharmaceuticals, Inc. shares in Q3 2020, an estimated $370K.
  • Schroder Investment Management Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 4 quarters.
  • Schroder Investment Management Group's Eagle Pharmaceuticals, Inc. position peaked at $11.6M in Q1 2020.
  • 171 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2020.

Based on Schroder Investment Management Group's 13F filing for Q3 2020, filed 13 Nov 2020.